This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CardioNet, Inc. Reports Second Quarter 2011 Financial Results

In accordance with Regulation G of the Securities and Exchange Commission, the table set forth below reconciles certain financial measures used in this press release that were not calculated in accordance with generally accepted accounting principles, or GAAP, with the most directly comparable financial measure calculated in accordance with GAAP.


Three Months Ended
June 30, 2011 June 30, 2010
Operating loss – GAAP $ (3,038) $ (2,162)
Nonrecurring charges (a)   1,816   1,726

Adjusted operating loss
$ (1,222) $ (436)
Net loss – GAAP $ (3,006) $ (2,142)
Nonrecurring charges (net of income taxes of $0 and $0, respectively) (a)   1,816   1,726
Adjusted net loss $ (1,190) $ (416)

Loss per diluted share – GAAP $ (0.12) $ (0.09)
Nonrecurring charges per share (a)   0.07   0.07
Adjusted loss per diluted share $ (0.05) $ (0.02)
(a)   In the second quarter of 2011, we incurred $1.5 million of nonrecurring charges largely related to the integration of Biotel’s operations, as well as $0.3 million for the forfeiture and acceleration of certain options. In the second quarter of 2010, we incurred $1.1 million of severance and other exit costs related to the restructuring of our sales and service organizations, as well as $0.6 million of other nonrecurring charges.

Three Months Ended
June 30, 2011   June 30, 2010
Cash provided by operating activities $ 3,389 $ 5,624
Capital expenditures   (1,280)   (1,248)
Free cash flow   2,109   4,376

Three Months Ended
June 30, 2011   June 30, 2010
Operating loss – GAAP $ (3,038) $ (2,162)
Depreciation and amortization expense   3,310   3,185
EBITDA   272   1,023

Reconciliation of Non-GAAP Financial Measures(In Thousands, Except Per Share Amounts)

4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs